Abstract
Breast and prostate cancer patients may experience physical and psychological distress, and a possible decrease in sleep quality. Subjective and objective methods measure different aspects of sleep quality. Our study attempted to determine differences between objective and subjective measurements of sleep quality using bivariate and Pearson’s correlation data analysis. Forty breast (n = 20) and prostate (n = 20) cancer patients were recruited in this observational study. Participants were given an actigraphy device (ACT) and asked to continuously wear it for seven consecutive days, for objective data collection. Following this period, they filled out the Pittsburgh Sleep Quality Index Questionnaire (PSQI) to collect subjective data on sleep quality. The correlation results showed that, for breast cancer patients, PSQI sleep duration was moderately correlated with ACT total sleeping time (TST) (r = −0.534, p < 0.05), and PSQI daytime dysfunction was related to ACT efficiency (r = 0.521, p < 0.05). For prostate cancer patients, PSQI sleep disturbances were related to ACT TST (r = 0.626, p < 0.05). Both objective and subjective measurements are important in validating and determining details of sleep quality, with combined results being more insightful, and can also help in personalized care to further improve quality of life among cancer patients.
Highlights
Breast and prostate cancers are among the first ten most common forms of cancer in Taiwan, with nearly 14,000 and 6000 cases, respectively, in 2017, and since these numbers have been growing [1]
16 breast cancer patients and 15 prostate cancer patients were included in the study
Our results show that breast cancer patients had an average total Pittsburgh Sleep Quality Index Questionnaire (PSQI) score close to 5 and prostate cancer patients had an average total PSQI
Summary
Breast and prostate cancers are among the first ten most common forms of cancer in Taiwan, with nearly 14,000 and 6000 cases, respectively, in 2017, and since these numbers have been growing [1]. Due to technological and medical advancements in the early detection and treatment of breast and prostate cancers, the reported number of cancer patients has increased [2] This trend has occurred in Taiwan, and in other parts of the world as well. The International Agency for Research on Cancer estimates the global prevalence to be roughly 1.67 million and 1.1 million for breast cancer and prostate cancer, respectively [3]. Both these cancer types have more favorable survival rates; this depends upon the development level in any given region and the availability of treatment facilities, stage of diagnosis, age, etc. In 2015, breast cancer was the most common cancer in women worldwide [4], whereas prostate cancer was reported as the most common cancer in men [5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
